Omeros Corporation (OMER)

Market Cap	909.03M +302.9%
Revenue (ttm)	9.89M
Net Income	86.17M
EPS	1.21
Shares Out	72.38M
PE Ratio	10.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,445,442
Open	12.25
Previous Close	11.84
Day's Range	11.90 - 12.59
52-Week Range	3.44 - 17.65
Beta	2.52
Analysts	Buy
Price Target	33.00 (+162.74%)
Earnings Date	Aug 13, 2026

About OMER

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2009
• Employees: 175
• Stock Exchange: NASDAQ
• Ticker Symbol: OMER
• Website: https://www.omeros.com

Analyst Summary

According to 3 analysts, the average rating for OMER stock is "Buy." The 12-month stock price target is $33.0, which is an increase of 162.74% from the latest price.

Price Target

$33.0

(162.74% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 3, 2026

Data Sources Report a data error